Kenneth Kolinsky

3.0k total citations · 1 hit paper
33 papers, 2.3k citations indexed

About

Kenneth Kolinsky is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kenneth Kolinsky has authored 33 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 21 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kenneth Kolinsky's work include Cancer-related Molecular Pathways (8 papers), Cancer Treatment and Pharmacology (7 papers) and Melanoma and MAPK Pathways (7 papers). Kenneth Kolinsky is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), Cancer Treatment and Pharmacology (7 papers) and Melanoma and MAPK Pathways (7 papers). Kenneth Kolinsky collaborates with scholars based in United States, Switzerland and New Zealand. Kenneth Kolinsky's co-authors include Kathryn Packman, Brian Higgins, David Heimbrook, Christian Tovar, Zoran Filipovic, Binh Thanh Vu, Weiguo Qing, James Rosinski, Lyubomir T. Vassilev and Ola Myklebost and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Kenneth Kolinsky

33 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

2006 553 citations Christian Tovar, James Rosinski et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenneth Kolinsky United States	19	1.3k	1.3k	350	326	294	33	2.3k
Carlos Becerra United States	24	1.4k 1.0×	1.1k 0.9×	398 1.1×	400 1.2×	379 1.3×	98	2.5k
Yuhong She United States	15	1.4k 1.1×	983 0.8×	365 1.0×	161 0.5×	208 0.7×	16	2.1k
David A. Proia United States	30	1.9k 1.4×	945 0.8×	376 1.1×	323 1.0×	362 1.2×	57	2.6k
Ian R. Watson Canada	22	1.3k 1.0×	842 0.7×	244 0.7×	358 1.1×	501 1.7×	40	2.2k
Scott A. Boerner United States	23	1.2k 0.9×	852 0.7×	337 1.0×	238 0.7×	334 1.1×	40	2.2k
Donna Headlee United States	24	1.5k 1.1×	1.1k 0.9×	559 1.6×	330 1.0×	328 1.1×	34	2.7k
Mary Varterasian United States	19	1.1k 0.9×	821 0.7×	266 0.8×	181 0.6×	156 0.5×	42	1.9k
Volker Wacheck Austria	35	2.3k 1.8×	1.0k 0.8×	480 1.4×	496 1.5×	474 1.6×	113	3.6k
Jingsong Yang United States	21	1.4k 1.0×	898 0.7×	227 0.6×	250 0.8×	137 0.5×	37	2.1k
Leslie A. Fecher United States	21	1.6k 1.2×	2.1k 1.7×	351 1.0×	788 2.4×	240 0.8×	49	3.2k

Countries citing papers authored by Kenneth Kolinsky

Since Specialization

Citations

This map shows the geographic impact of Kenneth Kolinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Kolinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Kolinsky more than expected).

Fields of papers citing papers by Kenneth Kolinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Kolinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Kolinsky. The network helps show where Kenneth Kolinsky may publish in the future.

Co-authorship network of co-authors of Kenneth Kolinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Kolinsky. A scholar is included among the top collaborators of Kenneth Kolinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Kolinsky. Kenneth Kolinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Higgins, Brian, Kelli Glenn, Antje‐Christine Walz, et al.. (2014). Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach. Clinical Cancer Research. 20(14). 3742–3752. 50 indexed citations

Tovar, Christian, Bradford Graves, Kathryn Packman, et al.. (2013). MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models. Cancer Research. 73(8). 2587–2597. 220 indexed citations

Higgins, Brian P., Kenneth Kolinsky, Kathleen Schostack, et al.. (2012). Efficacy of vemurafenib (V), a selective ^V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.. Journal of Clinical Oncology. 30(4_suppl). 494–494. 5 indexed citations

Higgins, Brian, Kenneth Kolinsky, Hong Yang, et al.. (2012). Efficacy of vemurafenib, a selective BRAF^V600E inhibitor, in combination with a MEK inhibitor in BRAF^V600E colorectal cancer models.. Journal of Clinical Oncology. 30(4_suppl). 488–488. 3 indexed citations

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2011). Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Research. 72(3). 779–789. 170 indexed citations

He, Wei, Leopoldo Luistro, Daisy Carvajal, et al.. (2011). High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097. Molecular Oncology. 5(3). 292–301. 38 indexed citations

Su, Fei, Huanming Yang, Brian Higgins, et al.. (2011). Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (PLX4032).. Journal of Clinical Oncology. 29(15_suppl). 8517–8517. 1 indexed citations

Daouti, Sherif, Brian Higgins, Kenneth Kolinsky, et al.. (2010). Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models. Molecular Cancer Therapeutics. 9(1). 134–144. 23 indexed citations

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2010). RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Research. 70(13). 5518–5527. 307 indexed citations

10.

Liu, Jinjun, Qingjie Ding, Brian Higgins, et al.. (2010). Pyrazolobenzodiazepines: Part I. Synthesis and SAR of a potent class of kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(20). 5984–5987. 11 indexed citations

11.

Tovar, Christian, Brian Higgins, Dayanand Deo, et al.. (2010). Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: Implications for therapy. Cell Cycle. 9(16). 3384–3395. 24 indexed citations

12.

Daouti, Sherif, Huisheng Wang, Wenhui Li, et al.. (2009). Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Research. 69(5). 1924–1932. 25 indexed citations

13.

Kolinsky, Kenneth, Yue Zhang, Ute Dugan, et al.. (2009). Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.. PubMed. 29(1). 91–8. 16 indexed citations

14.

Su, Fei, Hong Yang, Jianping Chen, et al.. (2007). Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents. Molecular Cancer Therapeutics. 6. 3 indexed citations

15.

Tovar, Christian, James Rosinski, Zoran Filipovic, et al.. (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proceedings of the National Academy of Sciences. 103(6). 1888–1893. 553 indexed citations breakdown →

16.

McDermott, Lee, Mary Ellen Simcox, Brian Higgins, et al.. (2005). RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry. 13(16). 4835–4841. 17 indexed citations

17.

Simcox, Mary Ellen, Brian Higgins, Lee McDermott, et al.. (2004). 189 Rodent pharmacokinetics and antiangiogenic activity of a pyrimidopyrimidine dual KDR/FGFR antagonist. European Journal of Cancer Supplements. 2(8). 59–59. 3 indexed citations

18.

Higgins, Brian, Kenneth Kolinsky, Melissa Smith, et al.. (2004). Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anti-Cancer Drugs. 15(5). 503–512. 126 indexed citations

19.

Gately, Maurice K., Daisy Carvajal, Suzanne E. Connaughton, et al.. (1996). Interleukin‐12 Antagonist Activity of Mouse Interleukin‐12 p40 Homodimer in Vitro and in Vivo. Annals of the New York Academy of Sciences. 795(1). 1–12. 118 indexed citations

20.

McIntyre, Kim W., George Stepan, Kenneth Kolinsky, et al.. (1991). Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.. The Journal of Experimental Medicine. 173(4). 931–939. 254 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact